Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is a data-driven healthcare technology company with a strong global presence and a focus on recurring customer revenue. Despite facing competition and potential risks, their partnerships and advancements in new applications make them a strong contender in the market. However, as they rely on external funding and have faced challenges in the past, investors should closely monitor their financials and expansion plans.

Bears say

Sophia Genetics is a healthcare technology company that offers a cloud-based platform for data-driven medicine and life sciences research. While the market potential for such technology is significant at $40B, SOPHiA Genetics is still experiencing losses and does not expect to approach profitability until 2026. Additionally, there are risks to consider, such as competition and cybersecurity breaches. Despite recent partnerships and customer acquisitions, the company will need to see continued growth and cost control in order to justify its current stock price.

SOPH has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 3 analysts, SOPH has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.